tetano
Editor, Senior Moderator
J Pediatr Hematol Oncol
. 2023 Jun 7.
doi: 10.1097/MPH.0000000000002691. Online ahead of print. COVID-19 in Pediatric Cancer Patients and Hematopoietic Stem Cell Transplant Recipients in a Tertiary Care Hospital in Argentina
Antonio Latella[SUP] 1 [/SUP], Sandra Gómez[SUP] 2 [/SUP], Marcela Palladino[SUP] 1 [/SUP], Marcelo Navia[SUP] 1 [/SUP], Andrea Mangano[SUP] 3 [/SUP], Daniela Borgnia[SUP] 3 [/SUP], Pedro Rino[SUP] 4 [/SUP], Claudia González[SUP] 1 [/SUP], María S Felice[SUP] 5 [/SUP], Adriana Rose[SUP] 5 [/SUP], Daniel Alderete[SUP] 5 [/SUP], Raquel Staciuk[SUP] 6 [/SUP], Mariana Roizen[SUP] 6 [/SUP], Lidia Fraquelli[SUP] 1 [/SUP]
Affiliations
The outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in cancer pediatric patients was initially uncertain. The objective of this study was to describe the characteristics and outcome of cancer patients and hematopoietic stem cell transplant recipients from 0 to 19 years with detectable SARS-CoV-2 from April 23, 2020, to April 30, 2022, treated in a tertiary-level hospital in Argentina. A total of 348 cases were registered in 339 patients. The median age was 89.5 (3 to 224) months. The sex was predominantly male: 193 (55.5%). The most common malignant disease was leukemia (42.8%). One hundred four cases (29.9%) had comorbidities. Of the 346 cases with an available blood count, 17.6% had a lymphocyte count <300/mm3. Fever was the most common symptom. In most cases (93.1%) presented asymptomatic or mild disease. Twenty-one cases (6%) presented severe or critical status. Eleven of 24 admissions to the intensive care unit were due to COVID-19 (coronavirus disease 2019). Eight patients (2.3%) died. Two deaths were attributable to SARS-CoV-2 (0.6%). Being older, having fever, lymphopenia at diagnosis, and having received hematopoietic stem cell transplant were associated with a more severe disease. Around 90% of the children continued their cancer treatment without any change.
. 2023 Jun 7.
doi: 10.1097/MPH.0000000000002691. Online ahead of print. COVID-19 in Pediatric Cancer Patients and Hematopoietic Stem Cell Transplant Recipients in a Tertiary Care Hospital in Argentina
Antonio Latella[SUP] 1 [/SUP], Sandra Gómez[SUP] 2 [/SUP], Marcela Palladino[SUP] 1 [/SUP], Marcelo Navia[SUP] 1 [/SUP], Andrea Mangano[SUP] 3 [/SUP], Daniela Borgnia[SUP] 3 [/SUP], Pedro Rino[SUP] 4 [/SUP], Claudia González[SUP] 1 [/SUP], María S Felice[SUP] 5 [/SUP], Adriana Rose[SUP] 5 [/SUP], Daniel Alderete[SUP] 5 [/SUP], Raquel Staciuk[SUP] 6 [/SUP], Mariana Roizen[SUP] 6 [/SUP], Lidia Fraquelli[SUP] 1 [/SUP]
Affiliations
- PMID: 37314943
- DOI: 10.1097/MPH.0000000000002691
The outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in cancer pediatric patients was initially uncertain. The objective of this study was to describe the characteristics and outcome of cancer patients and hematopoietic stem cell transplant recipients from 0 to 19 years with detectable SARS-CoV-2 from April 23, 2020, to April 30, 2022, treated in a tertiary-level hospital in Argentina. A total of 348 cases were registered in 339 patients. The median age was 89.5 (3 to 224) months. The sex was predominantly male: 193 (55.5%). The most common malignant disease was leukemia (42.8%). One hundred four cases (29.9%) had comorbidities. Of the 346 cases with an available blood count, 17.6% had a lymphocyte count <300/mm3. Fever was the most common symptom. In most cases (93.1%) presented asymptomatic or mild disease. Twenty-one cases (6%) presented severe or critical status. Eleven of 24 admissions to the intensive care unit were due to COVID-19 (coronavirus disease 2019). Eight patients (2.3%) died. Two deaths were attributable to SARS-CoV-2 (0.6%). Being older, having fever, lymphopenia at diagnosis, and having received hematopoietic stem cell transplant were associated with a more severe disease. Around 90% of the children continued their cancer treatment without any change.